Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NewGenIvf GroupNIVF -0.91%14 EV-to-EBIT is 0.62 as of Sep. 09, 2026, which is 59% above its 10-year median of 0.39. GuruFocus rates NIVF with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 476 Healthcare Providers & Services companies, NewGenIvf Group ranks better than 97.69% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
NewGenIvf Group's Enterprise Value for the quarter that ended in Dec. 2025 was $5.47 Mil.
NewGenIvf Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NewGenIvf Group EV-to-EBIT Related Terms
NewGenIvf Group EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for NewGenIvf Group's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, NewGenIvf Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NewGenIvf Group EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NewGenIvf Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where NewGenIvf Group's EV-to-EBIT falls into.
NewGenIvf Group's current Enterprise Value is $5.92 Mil.
NewGenIvf Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NewGenIvf Group (NIVF) has a EV-to-EBIT of 0.62 as of Sep. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on NewGenIvf Group and its competitors. This is 59% above median its historical median of 0.39. Over the past decade, NewGenIvf Group's EV-to-EBIT has ranged from 0.29 to 0.63. According to the industry distribution chart, NewGenIvf Group ranks #11 out of 476 companies in the Healthcare Providers & Services industry, placing it in the top 2.3%.
Is NewGenIvf Group's EV-to-EBIT too high?
NewGenIvf Group's current EV-to-EBIT of 0.62 is 59% above median its 10-year median of 0.39. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 0.63. The Healthcare Providers & Services industry median EV-to-EBIT is 15.16. NewGenIvf Group's value of 0.62 is 95.9% below this industry median. Based on the distribution chart, NewGenIvf Group ranks #11 out of 476 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, NewGenIvf Group has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does NewGenIvf Group's EV-to-EBIT compare to CDIX and RHEP?
According to the Healthcare Providers & Services industry distribution chart, NewGenIvf Group ranks #11 out of 476 companies for EV-to-EBIT. This places NewGenIvf Group in the top 2% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.16. NewGenIvf Group's value of 0.62 is 95.9% below this benchmark. Historically, NewGenIvf Group's own EV-to-EBIT has ranged from 0.29 to 0.63 over the past decade. While the company's 10-year median is 0.39 vs. the industry median of 15.16, NewGenIvf Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.16, based on 476 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NewGenIvf Group's current EV-to-EBIT of 0.62 is 95.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on NewGenIvf Group and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NewGenIvf Group's current EV-to-EBIT is 0.62, which is 59% above median its own 10-year median of 0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewGenIvf Group stock overvalued right now?
NewGenIvf Group (NIVF) has a current EV-to-EBIT of 0.62. The current EV-to-EBIT is 0.62, which is 59% above median its 10-year median of 0.39 and 95.9% below the Healthcare Providers & Services industry median of 15.16. NewGenIvf Group's overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For NewGenIvf Group (NIVF), the current EV-to-EBIT is 0.62 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NewGenIvf Group Ltd is a tech-forward, diversified, multi-jurisdictional entity capitalizing on emerging opportunities across real estate development, digital asset innovation, and reproductive health solutions. The company offers two services, namely: in vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and fertility referral services, like surrogacy and ancillary caring services. It derives maximum revenue from in vitro fertilization (IVF) treatment service. Its Geographical presence is in China / HK SAR, Thailand, Cambodia, U.S and Kyrgyzstan. The company derives maximum revenue from Kyrgyzstan.
14GF Score
Get the complete analysis for NIVF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NIVF has been successfully added to your 
